Previous 10 | Next 10 |
Summary Today, we look back in on small cap developmental concern Kura Oncology for the first time in two years. Last week, the company reported third quarter results and got a $25 million equity investment from drug giant Bristol Myers Squibb. An investment analysis follows i...
Kura Oncology, Inc. (KURA) Q3 2022 Earnings Conference Call November 3, 2022 8:00 am ET Corporate Participants Pete De Spain - Senior Vice President of Investor Relations Troy Wilson - President and Chief Executive Officer Tom Doyle - Senior Vice President of Fin...
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that four abstracts highlighting ziftomenib, the Company’...
Kura Oncology press release ( NASDAQ: KURA ): Q3 GAAP EPS of -$0.53 beats by $0.03 . Net loss for the third quarter of 2022 was $35.5 million, compared to a net loss of $33.4 million for the third quarter of 2021. Shares -1.4% PM. For further details see:...
– Abstract reporting updated data from KOMET-001 accepted for oral presentation at ASH – – First demonstration of durable clinical response with tipifarnib plus alpelisib in HNSCC – – AIM-HN trial of tipifarnib in HRAS mutant HNSCC closed to furt...
– $25 million equity investment from Bristol Myers Squibb at $18.25 per share – – Term loan facility from Hercules Capital provides up to $125 million – – Proceeds extend Kura’s cash runway into 2026, if term loan is fully drawn ...
Kura Oncology ( NASDAQ: KURA ) is scheduled to announce Q3 earnings results on Thursday, November 3rd, before market open. The consensus EPS Estimate is -$0.56 Over the last 3 months, EPS estimates have seen 2 upward revisions and 6 downward. For further deta...
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2022 financial results before ...
– First demonstration that precision combination therapies can achieve a durable clinical response in PIK3CA-dependent HNSCC – – Preclinical data support potential to address ~45% of HNSCC tumors that harbor HRAS overexpression and/or PIK3CA mutation – ...
SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Of...
News, Short Squeeze, Breakout and More Instantly...
2024-06-25 22:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 08:15:04 ET H.C. Wainwright analyst issues BUY recommendation for KURA on June 25, 2024 06:44AM ET. The previous analyst recommendation was Buy. KURA was trading at $21.08 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...
– Ziftomenib induces insulin production, improves insulin sensitivity and reduces insulin resistance in preclinical model of type 2 diabetes – – Kura advancing multiple, next-generation menin inhibitor drug candidates targeting diabetes and other metabolic diseases ...